Boston Scientific (Natick, Massachusetts) last month reported a “historic quarter,” saying its profit in the second quarter ended June 30 nearly tripled to $313 million, boosted by strong sales of its recently approved drug-eluting stents (DES) and favorable currency exchange rates.